First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $46M — +306% growth in a single year.
What Moves the Stock
1Phase 3 clinical trial data readouts for tarcocimab in wet AMD, DME, and RVO - particularly non-inferiority endpoints versus aflibercept and durability metrics (weeks between injections)
2FDA regulatory interactions including Biologics License Application (BLA) submission timing, acceptance, and approval decisions
3Partnership announcements for ex-US commercialization rights or specific indication licensing deals
4Competitive landscape developments including Regeneron's Eylea HD approval/uptake, Roche's faricimab market penetration, and biosimilar threats to legacy anti-VEGF products
5Capital raises and cash runway updates - biotech valuations highly sensitive to dilution risk and financing terms
6No current revenue - pre-commercial stage with tarcocimab tedromer in Phase 3 trials
7Future revenue dependent on regulatory approval and commercialization of tarcocimab across wet AMD, DME, and RVO indications
8Potential partnership/licensing revenue from geographic or indication-specific collaborations
growth/speculative - Attracts biotech-focused growth investors and hedge funds willing to accept binary risk for asymmetric upside…
Rising interest rates negatively impact Kodiak through multiple channels: (1) Higher discount rates compress NPV of future cash flows…
Watch on earnings: Phase 3 trial interim analysis and topline data release dates for wet AMD, DME, and RVO programs, Cash and equivalents balance versus quarterly burn rate to assess financing needs and timeline pressure, FDA correspondence and regulatory milestone achievements (BLA submission, acceptance, PDUFA date assignment).
One Sentence Summary:
Kodiak Sciences: the story is balanced — phase 3 clinical trial data readouts for tarcocimab in wet amd, dme, and rvo - particularly non-inferiority endpoints versus aflibercept.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.